Results from previous studies revealing a high heterogeneity and cross-reactivity of drug-specific T cell clones (TCC) in individual patients prompted us to analyze the degeneracy of drug-reactive TCR in detail. Hence, we analyzed the MHC restriction pattern of a panel of 100 drug-specific TCC isolated from different drug-allergic donors. We found that 28 of the tested clones showed an MHC allele-unrestricted drug recognition. Most of these clones were at the same time highly drug specific, i.e. they could only be stimulated by the original drug and not by any drug derivatives. In contrast, TCC with the ability to interact with different drug derivatives displayed a clearly MHC allele-restricted drug recognition. Therefore, we concluded that the TCR of these clones is mainly interacting with side chains of the appropriate drug molecules and hence able to tolerate alterations in the MHC molecule. Moreover, we tested all clones for additional alloreactivity and found that 27 clones could be stimulated by a self-MHC-peptide-drug complex as well as by a non-self-MHC-peptide complex. This cross-reactivity with allogeneic MHC molecules was substantially higher in drug-specific TCC compared to tetanus toxoid-specific clones from the same donors. This suggests that from the point of view of drug-specific TCR, non-self-MHCpeptide complexes have a higher incidence to mimic the 'original' self-MHC-peptide-drug complex and this may occur for TCR recognizing self-MHC-pathogen-derived peptide complexes. Finally, the biological functions of bispecific TCC were not influenced by the nature of the stimulating ligand. Both drug as well as allogeneic stimulation led to similar reaction patterns in the analyzed TCC.
Introduction
In addition to the recognition of pathogen-derived peptides drug metabolites and (ii) drugs like lidocaine or sulfamethoxazole (SMX) which are not per se chemically reactive. Covalent embedded in the groove of self-MHC molecules, T cells can also recognize non-peptide antigens (1). In addition to lipids, modification of serum or cellular proteins can lead to presentation of modified self structures (haptenated peptides) by MHC glycolipids (2) and carbohydrates (3), T cells can also be triggered by small mol. wt compounds such as drugs (4) or class I or class II molecules to reactive T cells (7-9). However, recent work has elucidated that covalent binding is not a contact sensitizers like TNP or metal salts (5).
Drugs like β-lactam antibiotics, sulfonamides or local anes-necessary prerequisite for drug presentation: preincubation and subsequent washing of antigen-presenting cells (APC) thetics are often responsible for allergic reactions in humans. The T cell involvement in such drug allergic reactions is well with chemically inert drugs like lidocaine or SMX did not lead to any detectable T cell responses (10,11). We postulated, established (for review, see 6). However, several molecular aspects of the recognition of drugs by the TCR of drug-therefore, that these compounds can associate with MHC and/or embedded peptides in a non-covalent way, forming reactive T cell clones (TCC) remain still unclear. In principle two groups of drugs can be distinguished: (i) chemically rather unstable trimolecular MHC-peptide-drug complexes.
Although self-MHC-restricted T cell recognition has suffi-reactive compounds with the ability to covalently modify side chains of amino acids such as β-lactam antibiotics or reactive cient specificity to discriminate between an enormous variety of antigenic peptides, recent studies on TCR recognition have well in 24-well plates. The following drug concentrations were used: amoxicillin (500 µg/ml), Pen G (500 µg/ml), lidocaine begun to emphasize the importance of a significant level of cross-reactivity on different peptides, which is necessary to (100 µg/ml) and SMX (200 µg/ml). CMϩ was added after 7 days of culture. After 14 days, bulk cultures were re-stimulated produce an adequate TCR repertoire capable of responding to the universe of pathogens (reviewed in 12). Several studies with autologous irradiated (4000 rad) PBMC and the respective antigen. Specific T cell lines (TCL) were cloned by limiting of the cross-reactivity and fine specificity pattern of drugspecific TCC revealed highly heterogeneous T cell responses dilution as described previously (20) . Growing TCC were expanded in CMϩ and re-stimulated every 14 days with in the analyzed donors (13-16).
It is generally agreed that alloreactivity is the result of cross-allogeneic irradiated (6000 rad) PBMC plus phytohemagglutinin (PHA, 1 µg/ml, Bacto; Difco, Detroit, MI). From three reactive recognition by self-MHC-restricted T cells and is not a function of a particular population of T cells that has escaped donors (KB, SE and SF; see Table 5 ), freshly isolated PBMC were additionally simulated with TT (5 µg/ml) and TT-specific the constraints of the thymic selection (17). A recent study form Daniel et al. proposes that the majority of the alloreactivity TCC were generated after cloning by limiting dilution as described above. represents a variation of self-restricted responses in which there is a shift in the relative contribution of the MHC and TCC from skin biopsies. Skin punch biopsies were taken from peptide residues toward the overall strength of binding dermal reaction centers from a patient allergic to amoxicillin between the TCR and the MHC-peptide ligand. More energy and a patient allergic to ceftriaxone (21) . T cells were isolated is provided by the TCR-MHC interactions and less from as described (21) . Briefly dermal T cells were cultured with the TCR-peptide interactions; however, the latter are still 25,000 irradiated allogeneic PBMC plus PHA (2 µg/ml) in 100 necessary to reach the threshold required for T cell activaµl CM in 96-well round-bottomed plates. Growing T cell lines tion (18) .
were expanded in CMϩ and subsequently cloned by limiting The aim of this study was to study the degeneracy of dilution as described (20) . the TCR of drug-specific TCC isolated from patients with hypersensitivity reactions to different drugs. We analyzed the Immunofluorescence and PCR-based TCR V β analysis MHC restriction pattern of the different clones as well as Monoclonality of the TCC used was proven either by staining a possible cross-recognition of allogeneic MHC alleles. In with a panel of 22 different mAb recognizing different V β gene addition we compared the activation mechanisms in products (Immunotech, Marseilles, France) or by RT-PCRbispecific clones. based TCR oligotyping as described previously (8). Additionally, cross-reactive clones were tested for TCR V α expression by RT-PCR-based TCR oligotyping as described (8).
Methods

Proliferation assay Culture media (CM)
In order to reveal the MHC restriction pattern as well as to CM consisted of RPMI 1640 supplemented with 10% pooled identify the alloreactive potential of the drug-or TT-specific heat-inactivated human antibody serum (Swiss Red Cross, TCC we used a panel of allogeneic HLA-typed PBMC from Bern, Switzerland), 25 mM HEPES buffer, 2 mM L-glutamine healthy donors (see Tables 2 and 3 ). HLA class II phenotyping (Seromed, Fakola, Basel, Switzerland), 25 µg/ml transferrin was performed by PCR amplification using sequence-specific (Biotest, Dreieich, Germany), 100 µg/ml streptomycin and primers (Protrans Endotell, Allschwil, Switzerland). To deter-100 U/ml penicillin. The culture medium CMϩ, used to culture mine the proliferation of the TCC to the different allogeneic TCC, was additionally enriched with 50 U/ml recombinant IL-PBMC, 5ϫ10 4 TCC were incubated either with 5ϫ10 4 of the 2 (obtained from Dr D. Wrann, Novartis Research Institute, respective irradiated PBMC or with 5ϫ10 3 autologous B-LCL Vienna, Austria).
in the presence or absence of the indicated drug or TT ( were pulsed with [ 3 H]thymidine (0.5 µCi) for the last 8 h to Generation of drug-or TT-specific TCC determine proliferation as described above.
TCC from peripheral blood mononuclear cells (PBMC). Freshly
FACS analysis of CD25, CD69 expression isolated PBMC from donors allergic to lidocaine (19) , βlactam antibiotics (13) and SMX (10) were stimulated with the For immunofluorescence analysis of CD25, CD69 expression, 5ϫ10 4 TCC cells were incubated with different concentrations corresponding drug in CM at a cell density of 2ϫ10 6 cells/ of the antigens; again, 2ϫ10 4 irradiated (6000 rad) HLA-concentration to achieve half-maximal proliferation and could therefore be classified as weak agonists. matched B-LCL were added to drug-stimulated cultures. After 12 h, the supernatant was harvested for cytokine measurement
We concluded that the drug-specific T cell responses in most of the analyzed patients were polyclonal and heterogen-and cells were washed in PBS containing 0.5 mM EDTA to break the conjugates. Cells were then stained either with eous. In addition, another preceding analysis revealed that certain drug-specific TCC displayed a MHC allele unrestricted anti-CD25-FITC (Dako Research, Besancon, France) or anti-CD69-FITC (PharMingen, San Diego, CA). Analysis was per-recognition pattern, implicating that they recognize non-polymorphic residues of the MHC molecules in addition to certain formed on a Coulter Epics XL-MCL flow cytometer (Beckman Coulter, Nyon, Switzerland). side chains of the drug molecule (23) . The aim of this study was to characterize the degeneracy of drug-specific TCC in Cytokine measurement detail. In order to do that we analyzed a total number of 100 drug-specific TCC isolated either from PBMC or from skin To detect cytokines produced after stimulation with the differbiopsies of seven different drug-allergic donors (see Table  ent antigens, supernatants of cells stimulated as described 2). To compare drug-specific TCC with clones specific for above were collected after 12 or 48 h and cytokines were pathogen-derived peptides we tested in addition a panel of quantified by a sandwich ELISA according to standard proto-58 TT-specific TCC obtained from three different TT-immuncols (PharMingen) (22) . Detection limits were 10 pg/ml. ized and drug-allergic patients (donors KB, SE and SF). In a first set of experiments, we analyzed the MHC restriction Measurement of TCR down-regulation pattern of both groups of clones. For that purpose we used For immunofluorescence analysis of CD25, CD69 expression, a panel of 10 different allogeneic PBMC expressing a wide TCR down-regulation induced by different compounds was variety of different HLA-DRB1 molecules. Most of the drugdetermined as described previously (10,16). TCC cells specific clones (72 out of 100 tested clones) recognized the (5ϫ10 4 ) were incubated with different concentrations of the respective antigen only in the presence of HLA-matched antigens in 200 µl CM in U-bottom microtiter plates; again, allogeneic APC as shown for clone DB3 in Table 3 . For this 2ϫ10 4 irradiated (6000 rad) HLA-matched B-LCL were added clone the ceftriaxone recognition is clearly HLA-DRB1*1101to drug-stimulated cultures. The plates were centrifuged at 1104 restricted. However, 28 of the tested clones showed a 1200 r.p.m. for 2 min to allow conjugate formation and drug-specific proliferative response irrespective of the HLA incubated at 37°C. After 12 h, cells were resuspended, phenotype of the APC used. As shown in Table 3 , clone washed in PBS containing 0.5 mM EDTA to break the conjug-ABH47 could be stimulated in the presence of amoxicillin by ates and stained with anti-CD3 (UCHT-1; Dako Diagnostics, any of the used allogeneic feeder cells. This phenomenon Zug, Switzerland) followed by an FITC-labeled goat anticould also be observed in TCC specific for non-covalently mouse Ig (Dako Diagnostics). Analysis was performed on a binding drugs such as lidocaine and SMX (see Table 5 and Coulter Epics XL-MCL flow cytometer (Beckman Coulter). The data not shown). The drug-specific response of all these absolute number of CD3 molecules per cell was estimated HLA allele-non-restricted clones could easily be blocked by by reference to a standard curve of beads coated with known addition of anti-DR mAb (data not shown). Thereby we amounts of mouse Ig (Qifikit; Dako Diagnostics). Cytokine could exclude that in these clones the drug molecules were production was measured in the culture supernatant using presented by HLA-DP or HLA-DQ, or by non-classical antigenan ELISA as described above.
presenting molecules such as CD1. None of the 58 tested TT-specific TCC showed an MHC allele-unrestricted antigen recognition.
Results
Furthermore, a third group of clones could be detected where the need of professional APC was not required: clone Heterogeneous MHC restriction pattern of drug-specific TCC H4 had the ability to recognize the drug SMX presented on MHC molecules expressed on the surface of the T cells In previous studies we showed that drug-specific TCC have a high heterogeneity in their ability to respond to different themselves (see Table 3 ). Twelve other clones from three different donors showed the same 'T cell responder' features drugs with the same core structure (13,15,16). Table 1 gives a summary of the observed cross-reactivity pattern of SMX-(data not shown and 20). specific TCC to a panel of different sulfonamide derivatives.
Alloreactivity of drug-specific TCC On one hand, nine TCC were isolated, which were highly specific as they could be stimulated by the parent drug SMX In addition to the above described clones, we could detect in total 27 clones which reacted in the absence of stimulatory only and did non-tolerate even slight modifications of the drug molecule. On the other hand, several clones, such as H9, drug molecules in an alloreactive manner to a certain nonself-MHC allele. By RT-PCR oligotyping of the TCR V α chains showed a broad cross-reactivity pattern in as much as they could recognize up to nine different compounds sharing only we could exclude that the additional alloreactivity of the drugspecific clones was due to expression of two different V α minor structural similarities (16). Interestingly, for several cross-reactive clones, such as 8.15, the different compounds chains. Table 4 shows the representative reactivity pattern of three alloreactive drug-specific TCC from three different stimulating these clones differed in their capacity to induce proliferation (data not shown and 16). Few compounds had donors. Clone OFB12 showed lidocaine recognition in the context of HLA-DRB1*1501-03 (donors WP and autologous the same full agonistic properties as the parent drug SMX, whereas other compounds needed a 10-to 100-fold higher B-LCL) and an additional alloreactivity to the HLA-DRB1*0801 to such altered peptide ligands (APL) include cytokine production in the absence of proliferation, differential cytokine production, anergy and antagonism of the response to the wild-type antigen (25) (26) (27) (28) . We therefore asked if allele (donors SK and CB). A similar pattern could be observed for clone H13 which recognized the stimulating drug SMX in the different antigenic structures (self-MHC-peptide-drug complexes versus non-self-MHC-peptide complexes) may the context of HLA-DRB1*1001 (donor KV and autologous B-LCL) and revealed alloreactivity to the HLA-DRB1*1303-04 elicit a similar reaction pattern in bispecific TCC. Two TCC, OFB12 and H13 (see Table 4 ), were analyzed in detail. As allele (donors MA, YH and SK). The same cross-reactivity could also be observed in TCC reactive to covalently binding previously shown, the kinetics of T cell triggering after drug stimulation resembled the ones observed after activation drugs such as Pen G and other β-lactam antibiotics: clone by allogeneic B-LCL (11). In addition, the comparison of triggering by different ligands. Both stimuli elicited production of a similar cytokine pattern and showed similar extents the dose-response curves in different readout systems, i.e. up-regulation of activation markers, proliferation and cytokine of TCR down-regulation required for the induction of halfmaximal effector functions (see Fig. 2 ). Therefore, we production, after drug and allogeneic stimulation did not show any significant differences (Fig. 1) . As the ligand concluded that in the case of the analyzed TCC the activation by different antigens such as self-MHC-peptide-density of APC presenting unstably associated drug molecules and APC bearing non-self-MHC-peptide complexes drug complexes and non-self-MHC-peptide complexes did not influence the biochemical events following TCR-ligand cannot be measured up directly, we compared the extent of different biological responses, measurable after TCR interaction.
Discussion
In this study we analyzed the influence of different HLA-DR alleles on the interaction of a drug-specific TCR with MHCpeptide-drug complexes. We found that 28 out of 100 tested drug-specific clones from different donors showed a proliferative response after drug stimulation irrespective of the presenting HLA-DR allele. Interestingly, this HLA allele-unrestricted drug presentation was found for clones that react to covalently binding drugs such as Pen G or amoxicillin as well as for clones specific for the non-covalently binding drugs lidocaine and SMX. As the responses could easily be blocked by addition of anti-DR mAb, we could exclude that these clones recognize the drug molecules in the context of other presenting molecules such as CD1. Similar observation have been made recently for nickel-specific T cells (29) , as well as for peptide-specific clones (30) . In addition, murine T cell hybridomas specific for the contact sensitizer TNP showed a similar freedom in their ability to tolerate different presenting MHC alleles (31) . It has been shown by crystallographic analysis of TCRligand interactions that the MHC residues that are engaged by the TCR are mostly conserved amino acids, which do not vary between different DR alleles (32, 33) . The TCR-MHCpeptide structures determined to date (34, 35) indicate that the required degree of peptide cross-reactivity can be produced in at least two ways: (i) the TCR 'focus' on only few amino acid side chains of the peptide and can accommodate the molecular basis of the recognition of drug molecules by the TCR of specific T cells (see Fig. 3 ): allele-restricted and allele-unrestricted clones vary in the degree by which MHC Table 1 ). The depicted MHC-peptide-drug complex shows a schematic view of the unstable, non-covalent association of a non-reactive drug (SMX) with a MHC-peptide complex. Notice that the thickness of the arrows corresponds to the energy provided for the overall strength of the TCR-ligand interaction. (A) In the case of highly drug-specific clones the TCR is mainly triggered by interactions with side chains of the drug molecule and therefore even slight alterations of the three-dimensional structure of the ligand surface (i.e. the drug molecule) are not tolerated. If the main part of the energy required for a productive TCR engagement is provided by the interaction of the TCR with the peptide-drug complex, then it seems feasible that alteration in the involved MHC residues may also be allowed. Therefore, highly specific TCC show mainly a MHC allele-unrestricted recognition. (B) Broadly drug-reactive TCC interact predominantly with amino acid residues of the MHC molecule and thus allow larger modifications of the embedded drug molecule. As a consequence, these clones show a clearly MHC allele-restricted recognition, as modifications of the relevant MHC residues abrogate the interaction. cells. In analogy, these drug-specific clones can also be TCC T cell clone TCL T cell line classified as 'T cell responder clones' (20) . The functional TT tetanus toxoid differences between 'responder' and 'non-responder' T cells have not yet been fully elucidated; however, the data obtained with peptide-specific clones indicate that these two groups of clones differ in their expression of co-stimulatory ligands, References mainly CD28 (20) . of T cells selected for self-restricted responses (37). This also 189:195. implies that alloreactive T cells are not a particular population 3 Corinti, S., De Palma, R., Fontana, A., Gagliardi, C., Pini, C. and of the mature T cell repertoire that has escaped the constraints Table 5 indicate that the degeneracy of drug-specific TCR 7 Brander, C., Mauri-Hellweg, D., Bettens, F., Rolli, H., Goldman, might be higher compared to peptide-specific TCR. As a
